Illustrative image – not actual.Ranbaxy Laboratories, through its Malaysian JV, Ranbaxy Malaysia Sdn Bhd, will set up a greenfield manufacturing unit for which it has allocated a site in Malaysia.
Ranbaxy owns 71 per cent stake in the JV. The project, spread across 15 acre, will entail an investment of $35 million (approx Rs 213.89 crore).
The company has already signed the 'letter of offer' agreement for the required land with Kulim Hi Tech Park, a wholly-owned state agency and industrial park that houses various leading industries. The tech park is located at Kulim, in the state of Kedah, Malaysia.
In addition to this, the company has also received approval from the Government of Malaysia to set up a greenfield manufacturing plant in September 2012.
The new unit will produce tablets and capsules primarily in the cardiovascular, anti-diabetic, anti-infective and gastrointestinal segments.
Once the plant becomes operational, Ranbaxy's total output in Malaysia will go up from one billion doses per year to three billion doses each year.
